Literature DB >> 11879205

Complete beta-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase.

Margarida F B Silva1, Jos P N Ruiter, Henk Overmars, Albert H Bootsma, Albert H van Gennip, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida, Ronald J A Wanders.   

Abstract

The beta-oxidation of valproic acid (VPA; 2-n-propylpentanoic acid) was investigated in vitro in intact rat liver mitochondria incubated with (3)H-labelled VPA. The metabolism of [4,5-(3)H(2)]VPA and [2-(3)H]VPA was studied by analysing the different acyl-CoA intermediates formed by reverse-phase HPLC with radiochemical detection. Valproyl-CoA, Delta(2(E))-valproyl-CoA,3-hydroxyvalproyl-CoA and 3-oxovalproyl-CoA (labelled and non-labelled) were determined using continuous on-line radiochemical and UV detection. The formation of these intermediates was investigated using the two tritiated precursors in respiratory states 3 and 4. Valproyl-CoA was present at highest concentrations under both conditions. Two distinct labelled peaks were found, which were identified as (3)H(2)O and [4,5-(3)H(2)]3-oxo-VPA. The formation of (3)H(2)O strongly suggested that VPA underwent complete beta-oxidation and that [4,5-(3)H(2)]3-oxo-VPA was formed by hydrolysis of the corresponding thioester. The hypothesis that 3-oxovalproyl-CoA undergoes thiolytic cleavage was investigated further. For this purpose a mito chondrial lysate was incubated with synthetic 3-oxovalproyl-CoA, carnitine and carnitine acetyltransferase for subsequent monitoring of the formation of propionylcarnitine and pentanoylcarnitine using electrospray ionization tandem MS. The detection of these compounds demonstrated unequivocally that the intermediate 3-oxovalproyl-CoA is a substrate of a mitochondrial thiolase, producing propionyl-CoA and pentanoyl-CoA, thus demonstrating the complete beta-oxidation of VPA in the mitochondrion. Our data should lead to a re-evaluation of the generally accepted concept that the biotransformation of VPA by mitochondrial beta-oxidation is incomplete.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11879205      PMCID: PMC1222442          DOI: 10.1042/0264-6021:3620755

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

1.  Quantitative plasma acylcarnitine analysis using electrospray tandem mass spectrometry for the diagnosis of organic acidaemias and fatty acid oxidation defects.

Authors:  P Vreken; A E van Lint; A H Bootsma; H Overmars; R J Wanders; A H van Gennip
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

2.  The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase.

Authors:  M Ito; Y Ikeda; J G Arnez; G Finocchiaro; K Tanaka
Journal:  Biochim Biophys Acta       Date:  1990-05-16

3.  Acetoacetyl CoA thiolase deficiency: a cause of severe ketoacidosis in infancy simulating salicylism.

Authors:  B H Robinson; W G Sherwood; J Taylor; J W Balfe; O A Mamer
Journal:  J Pediatr       Date:  1979-08       Impact factor: 4.406

4.  Synthesis and intramitochondrial levels of valproyl-coenzyme A metabolites.

Authors:  M F Silva; J P Ruiter; L IJlst; P Allers; H J ten Brink; C Jakobs; M Duran; I Tavares de Almeida; R J Wanders
Journal:  Anal Biochem       Date:  2001-03-01       Impact factor: 3.365

5.  The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies.

Authors:  J W Kesterson; G R Granneman; J M Machinist
Journal:  Hepatology       Date:  1984 Nov-Dec       Impact factor: 17.425

6.  The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats.

Authors:  D M Turnbull; A J Bone; K Bartlett; P P Koundakjian; H S Sherratt
Journal:  Biochem Pharmacol       Date:  1983-06-15       Impact factor: 5.858

7.  Action of the antiepileptic drug, valproic acid, on fatty acid oxidation in isolated rat hepatocytes.

Authors:  F X Coudé; G Grimber; A Pelet; Y Benoit
Journal:  Biochem Biophys Res Commun       Date:  1983-09-15       Impact factor: 3.575

8.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

9.  Comparison of the binding affinities of acyl-CoA-binding protein and fatty-acid-binding protein for long-chain acyl-CoA esters.

Authors:  J T Rasmussen; T Börchers; J Knudsen
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

10.  Influence of valproic acid on hepatic carbohydrate and lipid metabolism.

Authors:  C M Becker; R A Harris
Journal:  Arch Biochem Biophys       Date:  1983-06       Impact factor: 4.013

View more
  12 in total

Review 1.  Peroxisomal acyl-CoA synthetases.

Authors:  Paul A Watkins; Jessica M Ellis
Journal:  Biochim Biophys Acta       Date:  2012-02-17

2.  Competition between acetate and oleate for the formation of malonyl-CoA and mitochondrial acetyl-CoA in the perfused rat heart.

Authors:  Fang Bian; Takhar Kasumov; Kathryn A Jobbins; Paul E Minkler; Vernon E Anderson; Janos Kerner; Charles L Hoppel; Henri Brunengraber
Journal:  J Mol Cell Cardiol       Date:  2006-10-03       Impact factor: 5.000

3.  Impact of inborn errors of metabolism on admission in a neonatal intensive care unit--a prospective cohort study.

Authors:  Wenjun Tu; Jian He; Fang Dai; Xinyu Wang; Ying Li
Journal:  Indian J Pediatr       Date:  2011-06-10       Impact factor: 1.967

4.  Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.

Authors:  Luke A Wittenburg; Daniel L Gustafson; Douglas H Thamm
Journal:  Clin Cancer Res       Date:  2010-08-12       Impact factor: 12.531

5.  Role of isovaleryl-CoA dehydrogenase and short branched-chain acyl-CoA dehydrogenase in the metabolism of valproic acid: implications for the branched-chain amino acid oxidation pathway.

Authors:  Paula B M Luís; Jos P N Ruiter; Lodewijk Ijlst; Isabel Tavares de Almeida; Marinus Duran; Al-Walid Mohsen; Jerry Vockley; Ronald J A Wanders; Margarida F B Silva
Journal:  Drug Metab Dispos       Date:  2011-03-23       Impact factor: 3.922

Review 6.  Dihydrolipoamide dehydrogenase, pyruvate oxidation, and acetylation-dependent mechanisms intersecting drug iatrogenesis.

Authors:  I F Duarte; J Caio; M F Moedas; L A Rodrigues; A P Leandro; I A Rivera; M F B Silva
Journal:  Cell Mol Life Sci       Date:  2021-10-31       Impact factor: 9.261

7.  Glucose metabolism as a target of histone deacetylase inhibitors.

Authors:  Suzanne E Wardell; Olga R Ilkayeva; Heather L Wieman; Daniel E Frigo; Jeffrey C Rathmell; Christopher B Newgard; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2008-12-23

Review 8.  Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.

Authors:  M F B Silva; C C P Aires; P B M Luis; J P N Ruiter; L IJlst; M Duran; R J A Wanders; I Tavares de Almeida
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

9.  Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia.

Authors:  J Skavland; K M Jørgensen; K Hadziavdic; R Hovland; I Jonassen; O Bruserud; B T Gjertsen
Journal:  Blood Cancer J       Date:  2011-02-11       Impact factor: 11.037

10.  Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study.

Authors:  K E Price; R E Pearce; U C Garg; B A Heese; L D Smith; J E Sullivan; M J Kennedy; J F Bale; R M Ward; T K H Chang; F S Abbott; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2011-05-04       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.